Notice of Intent to Sole Source
The Centers for Disease Control and prevention intends to award a sole source firm fixed price purchase order to Sanofi Pasteur for a plaque titration to quantify the titer of Wetvax for the CDC Wetvax smallpox stability program. CDC current Wetvax smallpox vaccine IND 10812 Serial #008 June 7, 2004 submission and acceptance by the FDA of the Baseline Plaque Forming Unit Titer Determination of IND-Labeled Live Aventis Pasteur Smallpox Vaccine. The test and data submitted to the FDA had been developed by Sanofi Pasteur/Acamis. Their validated procedure for VERO cell plaque forming unit assay is the only accepted potency test that can be used under the current smallpox release protocal. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) and 10 U.S.C. 2304(c)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals.
This notice of intent is not a request for competitive quotations; however, all quotations/responses received within fifteen (15) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to William Brannen at [email protected] by 5:00 PM EST., July 2nd , 2014.
FAR REFERENCE: FAR 5.207- Preparation and transmittal of synopses under (c)(15), (c)(16) (i), and (c)(16)(ii).
William T. Brannen, Phone 7704882084, Email [email protected] - Lawrence R. McCoy, Contracting Officer, Phone 770-488-2087, Fax 770-488-2670, Email [email protected]
